NCT05924906View on ClinicalTrials.gov

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

July 31, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

NB002

Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

All Listed Sponsors

lead

Suzhou Neologics Bioscience Co., Ltd.

INDUSTRY